Clinical trial
Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant…
NCT00132756 · Morton Plant Mease Health Care, Other · Terminated
Key facts
| NCT number | NCT00132756 |
|---|---|
| Title | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer |
| Official title | Liposomal Doxorubicin and Estramustine Phosphate: A Phase II Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer |
| Lead sponsor | Morton Plant Mease Health Care, Other |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Doxil and Estramustine |
| Enrollment | 30 |
| Start date | Dec 1, 2003 |
| First posted | Aug 22, 2005 |
| Last update posted | Nov 8, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: